title: Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group.
abstract: A total of 241 men and women with mild to moderately severe chronic heart failure (New York Heart Association functional class II [90%] or III) and a mean (+/- SD) left ventricular ejection fraction of 25 +/- 7%, entered a 24-week, prospective, double-blind, placebo-controlled trial of 10 or 20 mg/day of fosinopril, a phosphinic acid angiotensin-converting enzyme inhibitor. Patients received concomitant diuretic therapy but not digitalis. Primary end points were mean change in maximal treadmill exercise time and occurrence of prospectively defined clinical events indicative of worsening heart failure (most to least severe): death, withdrawal for worsening heart failure, hospitalization for worsening heart failure, need for supplemental diuretic or emergency room visit for worsening heart failure, and no event. At study end point, treadmill exercise time had improved in the fosinopril versus the placebo group (+28.4 vs -13.5 seconds, p = 0.047). New York Heart Association functional class had improved at end point more frequently (24% vs 13%) and deteriorated less frequently (18% vs 32%) in the fosinopril group (p = 0.003). More patients treated with fosinopril (66% vs 50%) remained free of clinical events indicative of worsening heart failure, and fosinopril-treated patients had less severe clinical events (p = 0.004). Dyspnea, fatigue, and paroxysmal nocturnal dyspnea improved more often and worsened less often in this group (p < or = 0.002), and edema showed a trend toward improvement (p = 0.088). These clinical benefits did not require concomitant digitalis therapy. Fosinopril was associated with an acceptable safety profile.
authors.affiliation: Nassau County Medical Center, East Meadow, New York.
authors.forename: E J
authors.initials: EJ
authors.lastname: Brown
authors.forename: P H
authors.initials: PH
authors.lastname: Chew
authors.forename: A
authors.initials: A
authors.lastname: MacLean
authors.forename: K
authors.initials: K
authors.lastname: Gelperin
authors.forename: J P
authors.initials: JP
authors.lastname: Ilgenfritz
authors.forename: M
authors.initials: M
authors.lastname: Blumenthal
mesh_terms: D000368:Aged; D002908:Chronic Disease; D004232:Diuretics / Q000627:therapeutic use; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D017328:Fosinopril / Q000494:pharmacology*; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology*; D006334:Heart Function Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D004232:Diuretics; D017328:Fosinopril